COVID-19危重症对6个月时新发残疾、功能结局和重返工作的影响:一项前瞻性队列研究
这项全国代表性、多中心、前瞻性队列研究纳入30家医院212例COVID-19危重症患者,中位年龄61(51-70)岁,124例(58.5%)为男性。6个月时43/160(26.9%)患者死亡,42/108(38.9%)应答幸存者报告新发残疾。与病前相比,WHODAS百分比评分恶化(平均差10.40%[95%CI 7.06-13.77],p<0.001),EQ-5D-5LTM效用评分下降(平均差-0.19[-0.28至-0.10],p<0.001)。13例(11.4%)幸存者因健康不佳未重返工作,82/115(71.3%)报告持续症状;死亡或新发残疾的独立预测因素为疾病严重程度更高和衰弱增加。
要点
- 6个月时43/160(26.9%)患者死亡,42/108(38.9%)应答幸存者报告新发残疾。
- 与病前相比WHODAS百分比评分恶化,平均差10.40%(95%CI 7.06-13.77),p<0.001。
- EQ-5D-5LTM效用评分较病前下降,平均差-0.19(95%CI -0.28至-0.10),p<0.001。
- 13例(11.4%)幸存者因健康不佳未重返工作,82/115(71.3%)报告持续症状。
- 死亡或新发残疾的独立预测因素为疾病严重程度更高和衰弱增加。
适用人群与场景
- COVID-19危重症患者,来自30家医院,274例符合条件者中纳入212例,中位年龄61(51-70)岁,124例(58.5%)为男性。
研究设计与关键结果
- 研究类型:全国代表性、多中心、前瞻性队列研究;纳入212例COVID-19危重症患者。
- 主要终点:6个月死亡或新发残疾,43/160(26.9%)患者死亡,42/108(38.9%)应答幸存者报告新发残疾。
- WHODAS百分比评分较病前恶化,平均差10.40%(95%CI 7.06-13.77),p<0.001。
- EQ-5D-5LTM效用评分较病前下降,平均差-0.19(95%CI -0.28至-0.10),p<0.001。
- 13例(11.4%)幸存者因健康不佳未重返工作;82/115(71.3%)患者报告持续症状。
- 死亡或新发残疾的独立预测因素为疾病严重程度更高和衰弱增加。
证据类型、等级与局限
- 证据类型:前瞻性队列研究;临床试验注册号NCT04401254,注册日期2020年5月26日。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为COVID-19危重症后6个月死亡和新发残疾情况严重,超过三分之一的幸存者存在新发残疾且涉及所有功能领域。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There are few reports of new functional impairment following critical illness from COVID-19. We aimed to describe the incidence of death or new disability, functional impairment and changes in health-related quality of life of patients after COVID-19 critical illness at 6 months.
METHODS: In a nationally representative, multicenter, prospective cohort study of COVID-19 critical illness, we determined the prevalence of death or new disability at 6 months, the primary outcome. We measured mortality, new disability and return to work with changes in the World Health Organization Disability Assessment Schedule 2.0 12L (WHODAS) and health status with the EQ5D-5LTM.
RESULTS: Of 274 eligible patients, 212 were enrolled from 30 hospitals. The median age was 61 (51-70) years, and 124 (58.5%) patients were male. At 6 months, 43/160 (26.9%) patients died and 42/108 (38.9%) responding survivors reported new disability. Compared to pre-illness, the WHODAS percentage score worsened (mean difference (MD), 10.40% [95% CI 7.06-13.77]; p < 0.001). Thirteen (11.4%) survivors had not returned to work due to poor health. There was a decrease in the EQ-5D-5LTM utility score (MD, - 0.19 [- 0.28 to - 0.10]; p < 0.001). At 6 months, 82 of 115 (71.3%) patients reported persistent symptoms. The independent predictors of death or new disability were higher severity of illness and increased frailty.
CONCLUSIONS: At six months after COVID-19 critical illness, death and new disability was substantial. Over a third of survivors had new disability, which was widespread across all areas of functioning. Clinical trial registration NCT04401254 May 26, 2020.
参考来源
- Hodgson CL, Higgins AM, Bailey MJ, et al. The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective cohort study. Crit Care. 2021. PMID: 34749756. doi:10.1186/s13054-021-03794-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。